Zoetis Inc. $ZTS Stock Sold by Mill Capital Management LLC

Mill Capital Management LLC cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 6.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 162,288 shares of the company’s stock after selling 11,701 shares during the period. Mill Capital Management LLC’s holdings in Zoetis were worth $11,333,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. University of Texas Texas AM Investment Management Co. purchased a new position in Zoetis during the second quarter worth $25,000. Dunhill Financial LLC increased its position in Zoetis by 519.3% during the second quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock valued at $25,000 after acquiring an additional 296 shares during the last quarter. Cassaday & Co Wealth Management LLC bought a new position in Zoetis during the first quarter valued at $28,000. Root Financial Partners LLC raised its stake in shares of Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after acquiring an additional 103 shares during the period. Finally, Wellington Grp LLC raised its stake in shares of Zoetis by 6,675.0% in the first quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after acquiring an additional 267 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Down 0.2%

NYSE:ZTS opened at $80.88 on Tuesday. Zoetis Inc. has a twelve month low of $68.77 and a twelve month high of $147.93. The company has a market cap of $33.42 billion, a price-to-earnings ratio of 12.31, a price-to-earnings-growth ratio of 1.20 and a beta of 0.74. The stock has a fifty day simple moving average of $74.58 and a 200-day simple moving average of $94.83. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business’s revenue was down .2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Analysts anticipate that Zoetis Inc. will post 6.14 EPS for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis’s payout ratio is 34.93%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Piper Sandler dropped their price target on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. UBS Group decreased their price objective on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Friday, August 7th. Citigroup dropped their target price on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Barclays cut their target price on Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 1st. Finally, Zacks Research cut Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. Seven investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Hold” and a consensus target price of $98.07.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.